Despite progress in lymphoid malignancies, most are still incurable and lead to the death of the patient. The University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) is a highly successful translational research program that takes advantage of the combined strengths of the translational lymphoma programs of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Comprehensive Cancer Center - two NCI-designated comprehensive cancer centers. During the prior funding period, the UI/MC has been highly productive. Scientific accomplishments include translational studies exploring the potential of a novel therapeutic agent, immunostimulatory CpG ODN, as a potential treatment for B cell malignancies, development of novel approaches to imaging that could impact on our understanding of lymphoma biology, and investigation into biomarkers that could have a significant impact on management of lymphoma. Five early phase therapeutic clinical trials have been opened as part of the UI/MC SPORE, including four studies that have accrued subjects at both Iowa and Mayo. Since initiation of the UI/MC SPORE in 2002, 96 subjects have been enrolled on therapeutic trials and 17 on novel imaging trials. DNA and extensive clinical data have been collected on 1331 subjects at Iowa and Mayo as part of the UI/MC Lymphoma SPORE Molecular Epidemiologic Resource which will be increasingly valuable as a tool for identifying genetic factors that contribute to lymphomagenesis and response to therapy. ? ? This renewal application is designed to accelerate the progress of the UI/MC SPORE and consists of four research projects, four core resources, and the Career Development and Developmental Research Programs. Specific projects are as follows: ? ? 1) A novel approach to the immunotherapy of B cell malignancies ? 2) Signal transduction inhibitor therapy for lymphoma ? 3) Biology and Epidemiology of APRIL and BLyS in B-cell NHL ? 4) Regulatory T-cells in the tumor microenvironment of B-cell non-Hodgkin lymphoma Core resources include Administration, Biostatistics and Bioinformatics, Biospecimens, and Clinical Research that supports both clinical trials and the Molecular Epidemiology Resource of the UI/MC SPORE. ? ? All units within the UI/MC SPORE work to draw on the resources of both institutions to expedite the translation of discoveries into new and better approaches to the prevention and treatment of lymphoma. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-07
Application #
7486336
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Program Officer
Nothwehr, Steven F
Project Start
2002-09-11
Project End
2012-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
7
Fiscal Year
2008
Total Cost
$2,251,952
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Naik, Shruthi; Galyon, Gina D; Jenks, Nathan J et al. (2018) Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. Mol Cancer Ther 17:316-326
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73
Saad Aldin, Ehab; McNeely, Parren; Menda, Yusuf (2018) Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. Clin Nucl Med 43:195-198
Link, Brian K; Day, Bann-Mo; Zhou, Xiaolei et al. (2018) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol :
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Holahan, Heather M; Farah, Ronda S; Fitz, Sara et al. (2018) Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 57:1314-1319
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561

Showing the most recent 10 out of 387 publications